The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Background Metastatic breast cancer (MBC) treatment has changed substantially over time,
but we do not know whether survival post-metastasis has improved at the population level …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …

Importance Although many patients with end-stage cancer are offered chemotherapy to
improve quality of life (QOL), the association between chemotherapy and QOL amid …

In recent years, the nanotechnology has offered researchers the opportunity to solve the
problems caused by the vehicle of the standard and first formulation of paclitaxel (Taxol®) …

Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …

Breast cancer is the most common cause of cancer and cancer death worldwide. Although
most patients present with localized breast cancer and may be rendered disease-free with …

Taxanes are a key chemotherapy component for several malignancies, including metastatic
breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC) …

Background In the KATHERINE study (NCT01772472), patients with residual invasive early
breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth …